Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes

Lian Engelen; Søren Lund; Isabel Ferreira; Lise Tarnow; Hans-Henrik Parving; Jørgen Brodersen Gram; Kaj Winther; Oluf Borbye Pedersen; Tom Teerlink; Rob Barto; Coen D A Stehouwer; Allan A Vaag; Casper G Schalkwijk

doi:10.1530/EJE-10-0851

Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes

Lian Engelen, Søren Lund, Isabel Ferreira, Lise Tarnow, Hans-Henrik Parving, Jørgen Brodersen Gram, Kaj Winther, Oluf Borbye Pedersen, Tom Teerlink, Rob Barto, Coen D A Stehouwer, Allan A Vaag, Casper G Schalkwijk

15 Citations (Scopus)

Abstract

Metformin has been reported to reduce α-dicarbonyls, which are known to contribute to diabetic complications. It is unclear whether this is due to direct quenching of α-dicarbonyls or to an improvement in glycemic control. We therefore compared the effects of metformin versus repaglinide, an antihyperglycemic agent with an insulin-secreting mechanism, on the levels of the α-dicarbonyl 3-deoxyglucosone (3DG).

Original language	English
Journal	European Journal of Endocrinology
Volume	164
Issue number	3
Pages (from-to)	371-9
Number of pages	9
ISSN	0804-4643
DOIs	https://doi.org/10.1530/EJE-10-0851
Publication status	Published - 2011

Keywords

Carbamates
Confidence Intervals
Deoxyglucose
Diabetes Mellitus, Type 2
Humans
Hypoglycemic Agents
Metformin
Piperidines

Access to Document

10.1530/EJE-10-0851

Cite this

Engelen, L., Lund, S., Ferreira, I., Tarnow, L., Parving, H-H., Gram, J. B., Winther, K., Pedersen, O. B., Teerlink, T., Barto, R., Stehouwer, C. D. A., Vaag, A. A., & Schalkwijk, C. G. (2011). Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes. European Journal of Endocrinology, 164(3), 371-9. https://doi.org/10.1530/EJE-10-0851

Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes. / Engelen, Lian; Lund, Søren; Ferreira, Isabel et al.

In: European Journal of Endocrinology, Vol. 164, No. 3, 2011, p. 371-9.

Research output: Contribution to journal › Journal article › Research › peer-review

Engelen, L, Lund, S, Ferreira, I, Tarnow, L, Parving, H-H, Gram, JB, Winther, K, Pedersen, OB, Teerlink, T, Barto, R, Stehouwer, CDA, Vaag, AA & Schalkwijk, CG 2011, 'Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes', European Journal of Endocrinology, vol. 164, no. 3, pp. 371-9. https://doi.org/10.1530/EJE-10-0851

@article{5b38fe6cd82f41f5b9d244863ffc0e53,

title = "Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes",

abstract = "Metformin has been reported to reduce α-dicarbonyls, which are known to contribute to diabetic complications. It is unclear whether this is due to direct quenching of α-dicarbonyls or to an improvement in glycemic control. We therefore compared the effects of metformin versus repaglinide, an antihyperglycemic agent with an insulin-secreting mechanism, on the levels of the α-dicarbonyl 3-deoxyglucosone (3DG).",

keywords = "Carbamates, Confidence Intervals, Deoxyglucose, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Piperidines",

author = "Lian Engelen and S{\o}ren Lund and Isabel Ferreira and Lise Tarnow and Hans-Henrik Parving and Gram, {J{\o}rgen Brodersen} and Kaj Winther and Pedersen, {Oluf Borbye} and Tom Teerlink and Rob Barto and Stehouwer, {Coen D A} and Vaag, {Allan A} and Schalkwijk, {Casper G}",

year = "2011",

doi = "10.1530/EJE-10-0851",

language = "English",

volume = "164",

pages = "371--9",

journal = "European Journal of Endocrinology",

issn = "0804-4643",

publisher = "BioScientifica Ltd",

number = "3",

}

TY - JOUR

T1 - Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes

AU - Engelen, Lian

AU - Lund, Søren

AU - Ferreira, Isabel

AU - Tarnow, Lise

AU - Parving, Hans-Henrik

AU - Gram, Jørgen Brodersen

AU - Winther, Kaj

AU - Pedersen, Oluf Borbye

AU - Teerlink, Tom

AU - Barto, Rob

AU - Stehouwer, Coen D A

AU - Vaag, Allan A

AU - Schalkwijk, Casper G

PY - 2011

Y1 - 2011

N2 - Metformin has been reported to reduce α-dicarbonyls, which are known to contribute to diabetic complications. It is unclear whether this is due to direct quenching of α-dicarbonyls or to an improvement in glycemic control. We therefore compared the effects of metformin versus repaglinide, an antihyperglycemic agent with an insulin-secreting mechanism, on the levels of the α-dicarbonyl 3-deoxyglucosone (3DG).

AB - Metformin has been reported to reduce α-dicarbonyls, which are known to contribute to diabetic complications. It is unclear whether this is due to direct quenching of α-dicarbonyls or to an improvement in glycemic control. We therefore compared the effects of metformin versus repaglinide, an antihyperglycemic agent with an insulin-secreting mechanism, on the levels of the α-dicarbonyl 3-deoxyglucosone (3DG).

KW - Carbamates

KW - Confidence Intervals

KW - Deoxyglucose

KW - Diabetes Mellitus, Type 2

KW - Humans

KW - Hypoglycemic Agents

KW - Metformin

KW - Piperidines

U2 - 10.1530/EJE-10-0851

DO - 10.1530/EJE-10-0851

M3 - Journal article

C2 - 21205874

VL - 164

SP - 371

EP - 379

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 3

ER -

Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes

Abstract

Keywords

Access to Document

Fingerprint

Cite this